Abdel Kareem Azab

List of Publications by Year
in descending order

90 papers	5,772 citations	147566 31 h-index	76769 74 g-index
91 all docs	91 docs citations	91 times ranked	11363 citing authors

#	Article	IF	Citations
1	Liposomal phytohemagglutinin: In vivo Tâ€cell activator as a novel panâ€cancer immunotherapy. Journal of Cellular and Molecular Medicine, 2022, 26, 940-944.	1.6	7
2	Synthesis, equilibrium, and biological study of a C-7 glucose boronic acid derivative as a potential candidate for boron neutron capture therapy. Bioorganic and Medicinal Chemistry, 2022, 59, 116659.	1.4	5
3	Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. , 2022, 10, e003975.		33
4	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer Journal, 2022, 12, .	2.8	11
5	Localized Delivery of Cisplatin to Cervical Cancer Improves Its Therapeutic Efficacy and Minimizes Its Side Effect Profile. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1483-1494.	0.4	37
6	Synthesis and Characterisation of a Boron-Rich Symmetric Triazine Bearing a Hypoxia-Targeting Nitroimidazole Moiety. Symmetry, 2021, 13, 202.	1.1	0
7	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. Leukemia, 2021, 35, 2346-2357.	3.3	28
8	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	5
9	Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges. Cancers, 2021, 13, 2853.	1.7	9
10	Nanoparticle T cell engagers for the treatment of acute myeloid leukemia. Oncotarget, 2021, 12, 1878-1885.	0.8	8
11	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Scientific Reports, 2021, 11, 19343.	1.6	6
12	CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies. Leukemia Research Reports, 2021, 16, 100268.	0.2	10
13	Targeting E-selectin to Tackle Cancer Using Uproleselan. Cancers, 2021, 13, 335.	1.7	30
14	CXCR4-targeted PET imaging using ⁶⁴Cu-AMD3100 for detection of WaldenstrÃ¶m Macroglobulinemia. Cancer Biology and Therapy, 2020, 21, 52-60.	1.5	6
15	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nature Communications, 2020, 11, 6037.	5.8	51
16	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers, 2020, 12, 305.	1.7	56
17	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers, 2020, 12, 320.	1.7	24
18	Biomaterials for cancer immunotherapy. , 2020, , 499-526.		5

#	Article	IF	Citations
19	Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma. Blood, 2020, 136, 3-3.	0.6	3
20	Thermal Sensitive Liposomes Improve Delivery of Boronated Agents for Boron Neutron Capture Therapy. Pharmaceutical Research, 2019, 36, 144.	1.7	26
21	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American Journal of Hematology, 2019, 94, 1244-1253.	2.0	42
22	Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy. Blood Cancer Journal, 2019, 9, 68.	2.8	18
23	PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. Haematologica, 2019, 104, e310-e313.	1.7	10
24	Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. Journal of Controlled Release, 2018, 270, 158-176.	4.8	49
25	3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients. Blood, 2018, 132, 1987-1987.	0.6	0
26	Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. Cancer Biology and Therapy, 2017, 18, 101-105.	1.5	18
27	Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. European Journal of Haematology, 2017, 98, 529-541.	1.1	31
28	Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. Leukemia and Lymphoma, 2017, 58, 2916-2925.	0.6	30
29	<scp>CXCL</scp>12 and <scp>CXCR</scp>7 are relevant targets to reverse cell adhesionâ€mediated drug resistance in multiple myeloma. British Journal of Haematology, 2017, 179, 36-49.	1.2	63
30	Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma. Translational Oncology, 2017, 10, 632-640.	1.7	26
31	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. Oncotarget, 2017, 8, 109973-109984.	0.8	19
32	Drug Delivery Approaches for the Treatment of Cervical Cancer. Pharmaceutics, 2016, 8, 23.	2.0	65
33	Spotlight on ixazomib: potential in the treatment of multiple myeloma. Drug Design, Development and Therapy, 2016, 10, 217.	2.0	69
34	A Hypoxia-Targeted Boron Neutron Capture Therapy Agent for the Treatment of Glioma. Pharmaceutical Research, 2016, 33, 2530-2539.	1.7	16
35	A <scp>CD</scp>138â€independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. British Journal of Haematology, 2016, 173, 70-81.	1.2	20
36	Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma. Haematologica, 2016, 101, e307-e311.	1.7	11

#	Article	IF	Citations
37	3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?. Future Oncology, 2016, 12, 1545-1547.	1.1	10
38	Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma. Leukemia and Lymphoma, 2016, 57, 1677-1686.	0.6	20
39	The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckland, N Z), 2015, 3, 83.	1.9	1,372
40	Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib. BioMed Research International, 2015, 2015, 1-8.	0.9	27
41	Advancements in Tumor Targeting Strategies for Boron Neutron Capture Therapy. Pharmaceutical Research, 2015, 32, 2824-2836.	1.7	81
42	Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in WaldenstrÃ¶m Macroglobulinemia. Molecular Cancer Research, 2015, 13, 263-272.	1.5	23
43	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leukemia Research, 2015, 39, 1299-1308.	0.4	15
44	Stem Cell Transfusion Restores Immune Function in Radiation-Induced Lymphopenic C57BL/6 Mice. Cancer Research, 2015, 75, 3442-3445.	0.4	16
45	3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials, 2015, 73, 70-84.	5.7	120
46	The role of P-glycoprotein in drug resistance in multiple myeloma. Leukemia and Lymphoma, 2015, 56, 26-33.	0.6	81
47	The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Laboratory Investigation, 2014, 94, 881-892.	1.7	17
48	Targeting survival and cell trafficking in multiple myeloma and <scp>W</scp>aldenstrom macroglobulinemia using panâ€class <scp>I PI</scp>3<scp>K</scp> inhibitor, buparlisib. American Journal of Hematology, 2014, 89, 1030-1036.	2.0	14
49	The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. Molecular Cancer Research, 2014, 12, 1347-1354.	1.5	50
50	Molecularly Targeted Therapies in Multiple Myeloma. Leukemia Research and Treatment, 2014, 2014, 1-8.	2.0	43
51	PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. British Journal of Haematology, 2014, 165, 89-101.	1.2	34
52	Delivery systems for brachytherapy. Journal of Controlled Release, 2014, 192, 19-28.	4.8	16
53	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood, 2014, 124, 1905-1914.	0.6	32
54	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 5777-5777.	0.6	2

#	Article	IF	Citations
55	Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression. Clinical Cancer Research, 2013, 19, 3360-3368.	3.2	104
56	BM mesenchymal stromal cellâ€"derived exosomes facilitate multiple myeloma progression. Journal of Clinical Investigation, 2013, 123, 1542-1555.	3.9	661
57	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood, 2013, 122, 1947-1947.	0.6	4
58	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. Blood, 2013, 122, 3159-3159.	0.6	0
59	Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2012, 18, 91-104.	3.2	30
60	Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clinical Cancer Research, 2012, 18, 6609-6622.	3.2	14
61	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood, 2012, 119, 1468-1478.	0.6	103
62	LNA-mediated antiâ€"miR-155 silencing in low-grade B-cell lymphomas. Blood, 2012, 120, 1678-1686.	0.6	152
63	Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012, 120, 5002-5013.	0.6	121
64	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood, 2012, 119, 5782-5794.	0.6	268
65	CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells. Blood, 2012, 120, 4009-4009.	0.6	0
66	Integrin Î²7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood, 2011, 117, 6202-6213.	0.6	134
67	Defining the role of TORC1/2 in multiple myeloma. Blood, 2011, 118, 6860-6870.	0.6	72
68	Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2011, 17, 1753-1764.	3.2	43
69	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 1874-1874.	0.6	1
70	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. Blood, 2011, 118, 625-625.	0.6	2
71	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. Blood, 2011, 118, 471-471.	0.6	0
72	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. Blood, 2011, 118, 1804-1804.	0.6	0

#	Article	IF	Citations
73	Role of TORC1 and TORC2 in Multiple Myeloma. Blood, 2011, 118, 1815-1815.	0.6	1
74	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. Blood, 2011, 118, 3669-3669.	0.6	0
75	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. Blood, 2011, 118, 3934-3934.	0.6	0
76	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2728-2728.	0.6	0
77	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. Blood, 2011, 118, 2424-2424.	0.6	0
78	microRNA-dependent modulation of histone acetylation in WaldenstrÃ¶m macroglobulinemia. Blood, 2010, 116, 1506-1514.	0.6	114
79	Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood, 2010, 115, 559-569.	0.6	93
80	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood, 2009, 113, 6669-6680.	0.6	297
81	microRNA expression in the biology, prognosis, and therapy of WaldenstrÃ¶m macroglobulinemia. Blood, 2009, 113, 4391-4402.	0.6	113
82	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113, 4341-4351.	0.6	398
83	RhoA and Rac1 GTPases play major and differential roles in stromal cellâ€"derived factor-1â€"induced cell adhesion and chemotaxis in multiple myeloma. Blood, 2009, 114, 619-629.	0.6	103
84	Response: Sensitization initiated. Blood, 2009, 114, 926-927.	0.6	1
85	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. Blood, 2009, 114, 1785-1785.	0.6	1
86	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 3732-3732.	0.6	2
87	Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. Blood, 2009, 114, 3843-3843.	0.6	0
88	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 4911-4911.	0.6	3
89	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 4916-4916.	0.6	1
90	SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood, 2008, 112, 150-158.	0.6	115